prostate cancer

Research in Review

Palliative Drugs In Combination With Docetaxel Can Improve Prostate Cancer Care

02/23/2016

JCP Editors

A clinical trial has shown that combining the chemotherapy drug docetaxel with other treatments can improve clinical outcomes in patients with bony metastatic castrate-refractory prostate cancer (CRPC). The...

A...

02/23/2016

Journal of Clinical Pathways

Clinical Insights

Prostatic Artery Embolization for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: Articles From the Official Show Daily for Synergy 2015

02/15/2016

Francisco Cesar Carnevale , MD, PhD;

Shivank S. Bhatia , MD;

The standard management of benign prostatic obstruction (BPO) is based on the overall health of the patient, on the severity of the lower urinary tract symptoms (LUTS), and on quality-of-life considerations. Voiding difficulties attributable...

The standard management of...

02/15/2016

IO Learning

Research in Review

Enzalutamide Improves Survival Over Bicalutamide in Castration-Resistant Prostate Cancer

02/02/2016

JCP Editors

Treatment with enzalutamide rather than bicalutamide for nonmetastatic or metastatic castration-resistant prostate cancer (CRPC) improves survival, according to results of a phase 2 clinical trial. CRPC occurs when...

...

02/02/2016

Journal of Clinical Pathways

Research in Review

Bankruptcy Associated with Increased Mortality Risk for Patients with Cancer

01/29/2016

JCP Editors

A new study suggests that financial stress, rooted in filing for bankruptcy, may be a risk factor for increased mortality after a cancer diagnosis. Patients with cancer are more likely than the general population to...

A new...

01/29/2016

Journal of Clinical Pathways

Conference Coverage

2016 Genitourinary Cancers Symposium

01/28/2016

JCP Editors

The American Society of Clinical Oncology’s 2016 Genitourinary Cancers Symposium was held earlier this month (January 7-9) in San Francisco, California, where the brightest professionals in urology, oncology, and...

The...

01/28/2016

Journal of Clinical Pathways

Research in Review

Earlier Chemotherapy Improves Outcomes for Patients With Prostate Cancer

12/30/2015

JCP Editors

Results from a recent clinical trial have shown that earlier chemotherapy treatment may lead to improved outcomes for prostate cancer patients initiating long-term hormone therapy. A paper published in Lancet...

...

12/30/2015

Journal of Clinical Pathways

News

FDA Fully Approves Non-Invasive HIFU Treatment for Prostate Cancer

12/03/2015

TORONTO, Dec. 3, 2015 /PRNewswire/ -- The FDA has fully approved the non-surgical, non-invasive treatment for prostate cancer known as HIFU or High Intensity Focused Ultrasound Therapy.  The Food and Drug Administration approved HIFU...

TORONTO, Dec. 3, 2015...

12/03/2015

IO Learning

Interview

Focus on Treatment of Prostate Disease During Opening of 5th-Anniversary Interventional Oncology Meeting

11/06/2015

By Jennifer FordOn November 5, 2015, the Synergy 2015 meeting had a successful start, celebrating 5 years of a multidisciplinary approach to interventional cancer care. The meeting welcomed nearly 500 registrants to Miami for this year’s...

By Jennifer FordOn November 5,...

11/06/2015

IO Learning

News

FDA Approves First Focused Ultrasound System for Treating the Prostate

10/13/2015

Newswise — Charlottesville, Virginia, October 13, 2015 -- The US Food and Drug Administration has approved SonaCare Medical’s Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables...

Newswise — Charlottesville,...

10/13/2015

IO Learning

News

Philips and Profound Medical Collaborate to Support Transurethral Ultrasound Ablation for Prostate Cancer

07/21/2015

July 21, 2015 07:15 AM Eastern Daylight TimeBEST, Netherlands & TORONTO--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX : PHIA) and Profound Medical Corp. (TSXV: PRN), a Toronto-based medical device company, today announced that they have...

July 21, 2015 07:15 AM Eastern...

07/21/2015

IO Learning